精神保健研究所 精神疾患病態研究部。私たちは「脳とこころの科学」の先駆的研究活動を展開しています。

統合失調症:生体バイオマーカー/死後脳

  • ホーム »
  • 統合失調症:生体バイオマーカー/死後脳

生体バイオマーカーとしては、主に血漿を用いた研究をしています。それ以外に、血中のRNAや血清の収集も行っており、自由に使って研究することができます。死後脳に関しては、国内外の共同研究者から提供を受けて、研究を行っています。

  1. Watanabe T, Ichikawa T, Toriumi K, Horiuchi Y, Kobori A, Kushima I, Hashimoto R, Fukumoto M, Koike S, Ujike H, Arinami T, Tatebayashi Y, Kasai K, Takeda M, Ozaki N, Okazaki Y, Yoshikawa T, Amano N, Washizuka S, Yamamoto H, Miyata T, Itokawa M, Yamamoto Y, Arai M. The regulation of soluble receptor for AGEs contributes to carbonyl stress in schizophrenia. Biochem Biophys Res Commun, (in press)
  2. Inoshita M, Numata S, Tajima A, Kinoshita M, Umehara H, Nakataki M, Ikeda M, Maruyama M, Yamamori H, Kanazawa T, Shimodera S, Hashimoto R, Imoto I, Yoneda H, Iwata N, Ohmori T. A significant causal association between C-reactive protein levels and schizophrenia. Sci Rep, 6:26105, 2016.5
  3. *Nakazawa T, *Hashimoto R, Sakoori K, Sugaya Y, Tanimura A, Hashimotodani Y, Ohi K, Yamamori H, Yasuda Y, Umeda-Yano S, Kiyama Y, Konno K, Inoue T, Yokoyama K, Inoue T, Numata S, Ohnuma T, Iwata N, Ozaki N, Hashimoto H, Watanabe M, Manabe T, Yamamoto T, Takeda M, *Kano M. Emerging Roles of ARHGAP33 in Intracellular Trafficking of TrkB and Pathophysiology of Neuropsychiatric Disorders. Nat Commun, 7:10594, 2016.2
  4. Ohi K, Ursini G, Li M, Shin J.H.,Ye T, Chen Q, Tao R, Kleinman JE., Hyde TM., Hashimoto R, Weinberger DR. DEGS2 polymorphism associated with cognition in schizophrenia is associated with gene expression in brain. Transl Psychiatry, 14;5:e550, 2015.4
  5. Kinoshita M, Numata S, Tajima A, Ohi K, Hashimoto R, Shimodera S, Imoto I, Takeda M, Ohmori T. Aberrant DNA methylation of blood in schizophrenia by adjusting for estimated cellular proportions. Neuromolecular Med, 16:697-703, 2014.12
  6. Yamamori H, *Hashimoto R, Fujita Y, Numata S, Yasuda Y, Fujimoto M, Ohi K, Umeda-Yano S, Ito A, Ohmori T, Hashimoto K, Takeda M. Changes in plasma D-serine, L-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment. Neurosci Lett, 582:93-8, 2014.10
  7. Nishi A, Numata S, Tajima A, Kinoshita M, Kikuchi K, Shimodera S, Tomotake M, Ohi K, Hashimoto R, Imoto I, Takeda M, Ohmori T. Meta-analyses of blood homocysteine levels for gender and genetic association studies of the MTHFR C677T polymorphism in schizophrenia. Schizophr Bull, 40(5):1154-63, 2014.9
  8. Umeda-Yano S, *Hashimoto R, Yamamori H, Wickertd CS, Yasuda Y, Ohi K, Fujimoto M, Ito A, Takeda M. Expression analysis of the genes identified in GWAS of the postmortem brain tissues from patients with schizophrenia. Neurosci Lett, 568:12-16, 2014.3
  9. Miyashita M, Arai M, Yuzawa H, Ichikawa T, Nohara I, Arai M, Obata N, Toriumi K, Kobori A, Niizato K, Ooshima K, Kushima I, Hashimoto R, Fukumoto M, Koike S, Toyota T, Ujike H, Arinami T, Kasai K, Takeda M, Ozaki N, Okazaki Y, Yoshikawa T, Amano N, Miyata T, Itokawa M. Replication of enhanced carbonyl stress in a subpopulation of schizophrenia. Psychiatry Clin Neurosci, 68(1):83-4, 2014.1
  10. Yamamori H, *Hashimoto R, Ishima T, Kishi F, Yasuda Y, Ohi K, Fujimoto M, Umeda-Yano S, Ito A, Hashimoto K, Takeda M. Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine. Neurosci Lett, 556(2013):37-41, 2013.11
  11. Okada T, *Hashimoto R, Yamamori H, Umeda-Yano S, Yasuda Y, Ohi K, Fukumoto M, Ikemoto K, KUnii Y, Tomita H, Ito A, Takeda M. Expression analysis of a novel mRNA variant of the schizophrenia risk gene ZNF804A. Schizophr Res, 141(2-3):277-8, 2012.11
  12. Ohi K, *Hashimoto R, Yasuda Y, Fukumoto M, Yamamori H, Umeda-Yano S, Okada T, Kamino K, Morihara T, Iwase M, Kazui H, Numata S, Ikeda M, Ohmura T, Iwata N, Ueno S, Ozaki N, Ohmori T, Arai H, Takeda M. Functional genetic variation at the NRGN gene and schizophrenia: evidence from a gene-based case-control study and gene expression analysis. Am J Med Genet B Neuropsychiatr Genet, 159B(4):405-13, 2012.6
  13. Yamamori H, *Hashimoto R, Ohi K, Yasuda Y, Fukumoto M, Kasahara E, Sekiyama A, Umeda-Yano S, Okada T, Iwase M, Kazui H, Ito A, Takeda M. A promoter variant in the Chitinase 3-Like 1 gene is associated with serum YKL-40 level and personality trait. Neurosci Lett, 513(3):204-208, 2012.2
  14. Yamamori H, *Hashimoto R, Verrall L, Yasuda Y, Ohi K, Fukumoto M, Umeda-Yano S, Ito A, Takeda M. Dysbindin-1 and NRG-1 gene expression in immortalized lymphocytes from patients with schizophrenia. J Hum Genet, 56(7):478-83, 2011.7
  15. Numata S, Ueno S, Iga J, Yamauchi K, Hongwei S, Hashimoto R, Takeda M, Kunugi H, Itakura M, Ohmori T. Gene expression in the peripheral leukocytes and association analysis of PDLIM5 gene in schizophrenia. Neurosci Lett, 415:28-33, 2007.1
  16. Law AJ, Lipska BK, Weickert CS, Hyde TM, Straub RE, Hashimoto R, Harrison PJ, Kleinman JE, Weinberger DR. Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5′ SNPs associated with the disease. Proc Natl Acad Sci USA, 103(17):6747-6752, 2006.4
PAGETOP
Copyright © 2019 Department of Pathology of Mental Diseases All Rights Reserved.